Phillip Meikle Joins Bone Biologics Board of Directors

Bone Biologics Corporation has appointed Phillip T. Meikle to its Board of Directors to succeed Don R. Hankey, who retired from the governing body after seven years. The assignation does not change the board’s four-person membership total.

Meikle most recently was president and CEO of Biosystems of New England Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He has broad experience representing diverse orthopedic and spine industry companies in developing and distributing products. Meikle has been a consultant to Stryker Spine for the past five years.

Biosystems of New England was a distributor for Stryker Spine from 2002 to 2019, and for Medtronic Spine from 1992 to 2002.

“The appointment of Phillip Meikle to our board of directors is particularly timely as we work to develop NB1 for spinal fusion patients. He brings a wealth of experience with orthopedic and spine products, and we look forward to benefitting from his knowledge, experience and industry relationships. We are delighted that a professional of Phil’s stature has agreed to join our board,” Bone Biologics President/CEO Jeffrey Frelick said. “On behalf of Bone Biologics and our board of directors, I extend heartfelt thanks to Don Hankey for his service as chairman and his longstanding support of our company, without which we would not be where we are today.”

Meikle earned a bachelor of science degree from West Virginia University College of Engineering. He has received numerous professional awards including Inaugural Inductee in the Stryker Spine Hall of Fame and Distributor of the Year at both Stryker and Medtronic Danek Spine.

Bone Biologics was founded to pursue regenerative medicine for bone. The company is undertaking work with select strategic partners that build on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures while additionally having rights to trauma and osteoporosis applications.